Conversely, prostate growth due to cancer is indeed serious. In cases of BPH, the prostate growth is noncancerous and is often no cause for concern. The main causes of prostate enlargement are benign prostate hyperplasia due to hormonal changes, prostate cancer, and chronic prostatitis. Symptoms of BPH may also be a sign of a more serious condition, such as prostate cancer. With the right monitoring and communication, many men with BPH can still enjoy the benefits of testosterone therapy. In men with both low testosterone and BPH, these two specialists often work together to find the safest and most effective treatment plan. A urologist is a doctor who specializes in prostate and urinary problems. The AUA states that TRT should be used only when clear symptoms of low testosterone are present and confirmed by blood tests. Doctors may also ask for imaging of the prostate, such as an ultrasound or MRI, if the prostate feels large or if PSA levels are higher than expected. While TRT can offer significant benefits, it’s crucial to understand the potential risks and to discuss them thoroughly with your doctor, particularly concerning prostate health. Research into prostate cancer relies on a number of laboratory models to test aspects of the disease. From 2016 to 2020, more than $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. However, an analysis of internet searches suggests neither event changes the level of prostate cancer interest or discussion much, in contrast to the more established Breast Cancer Awareness Month. After additional trials in 2015, docetaxel use was extended to those with castration-sensitive prostate cancer. Schally was awarded the 1977 Nobel Prize in Physiology or Medicine for his work on GnRH and prostate cancer. However, occasional experimentation over the next century bore mixed results, likely due to the inability to separate prostate tumors from prostates enlarged due to benign prostatic hyperplasia. A comprehensive evaluation by a medical professional, including prostate cancer screening, is vital to determine if TRT is appropriate. Several misconceptions surround the relationship between TRT and prostate cancer. The purpose of this screening is to identify any existing, undiagnosed prostate cancer. Before initiating TRT, men should undergo thorough prostate cancer screening. According to the National Institutes of Health, BPH affects approximately 50% of males ages 51–60 years old. The prostate gland makes some of the fluid that goes into semen. Symptoms include increased urinary frequency and urgency. NIDDK translates and disseminates research findings to increase knowledge and understanding about health and disease among patients, health professionals, and the public. Those who have low blood PSA levels at diagnosis, and whose tumors have a low Gleason grade and less-advanced clinical stage tend to have better prognoses. Around 80% of prostate cancer diagnoses are in men whose cancer is still confined to the prostate. As those severely ill with metastatic prostate cancer approach the end of their lives, most experience confusion and may hallucinate or have trouble recognizing loved ones. People with prostate cancer are around twice as likely to experience anxiety or depression compared to those without cancer. General weakness can also be caused by anemia, itself caused by a combination of the disease itself, poor nutrition, and damage to the bone marrow from cancer treatments or bone metastases. Metastases compress the spinal cord in up to 12% of those with metastatic prostate cancer causing pain, weakness, numbness, and paralysis. Those whose tumors have defective DNA damage repair benefit from treatment with the immune checkpoint inhibitor drug pembrolizumab and PARP inhibitors, namely olaparib, rucaparib, or niraparib.
